About InCarda

Committed to developing transformative therapies for cardiac conditions.

InCarda Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. The advantage of inhalation is that it delivers “first pass” to cardiac tissue, presenting a bolus of a drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and more importantly can be patient administered.

The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.

Our Mission

We are committed to developing transformative therapies to treat cardiac conditions. Our mission is to deliver drugs straight to the heart through the lungs, to provide for more rapid treatment and potentially improve long-term health.

Our Investors

Morningside Ventures

InCarda’s lead investor is Morningside Ventures. Other investors include a consortium of physicians and other health care and high tech professionals. Morningside is a diversified investment group founded in 1986. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, and since 1992, in mainland China. Morningside is an active investor in early-stage companies founded around novel life science and medical technology.

Our Novel Approach

Our approach is designed to reduce the risk normally associated with drug development.
Our model is based on the following three tenets:

approach-knowndiseases

Known Heart Conditions

InCarda’s products target known heart diseases & conditions.

Known Drugs

Approved Drugs

Our unique dosing paradigm treats heart conditions using approved drugs.

New Delivery

New Delivery

Our novel, inhaled products target regions of the heart where cardiac conditions arise.

For more information about InCarda: